Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Esorubicin"'
Autor:
I.W. Simson, Hendre C. Falkson, Geoffrey Falkson, Daniel G. Haller, Thomas J. Smith, Avital Cnaan, Yogeshwar Dayal
Publikováno v:
American Journal of Clinical Oncology. 13:510-515
We analyzed 56 of 75 previously untreated patients with hepatocellular carcinoma who entered on a prospectively randomized trial of acivicin versus 4'deoxydoxorubicin (esorubicin). At least one episode of severe toxicity was documented in 23% of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7ec89796788df5f40f794a6135f898
https://doi.org/10.1097/00000421-199012000-00012
https://doi.org/10.1097/00000421-199012000-00012
Autor:
N Colombo, Michael D. Green, James L. Speyer, J C Wernz, Uziel Beller, Franco M. Muggia, E M Beckman
Publikováno v:
Investigational New Drugs. 8:333-336
Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5156645991cfbb6bdd70371f711f29
https://doi.org/10.1007/bf00171850
https://doi.org/10.1007/bf00171850
Autor:
N. J. Vogelzang, D. Van Echo, W. Wood, Mary Alice Rice, A. H. Korzun, Hyman B. Muss, I. C. Henderson, T. Campbell
Publikováno v:
American Journal of Clinical Oncology. 13:233-237
Forty-six eligible women with advanced metastatic breast cancer were entered on a Phase II trial utilizing esorubicin (4'-deoxydoxorubicin) given in a dosage of 30 mg/m2 intravenously every 3 weeks. No patient had received anthracyclines or cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8c51f2f722ff1128092b37a9fd40b92
https://doi.org/10.1097/00000421-199006000-00011
https://doi.org/10.1097/00000421-199006000-00011
Autor:
Mark R. Green, Kathleen J. Propert, Caron Modeas, Q. Scott Ringenberg, Michael C. Perry, Larry Norton, Raymond B. Weiss, Hyman B. Muss, Richard L. Schilsky
Publikováno v:
Investigational New Drugs. 8:221-226
Esorubicin (4'-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer. Based on in vitro and animal data, esorubicin may possess less myocardial toxicity when compared to doxorubicin. One hundred thirty-six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f068f705829cbf6edd86ed3c89bb433
https://doi.org/10.1007/bf00177265
https://doi.org/10.1007/bf00177265
Autor:
D Stock-Novack, Thomas M. Abbott, Nancy Mason-Liddil, Robert O’Toole, S E Salmon, David S. Alberts
Publikováno v:
American journal of clinical oncology. 15(2)
Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. Eligibility criteria included measurable disease; performance status (SWOG) 0-2; no more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f28d62592cf0d83f1b625c79089ce1
https://pubmed.ncbi.nlm.nih.gov/1553903
https://pubmed.ncbi.nlm.nih.gov/1553903
Autor:
Darryl L. Wallace, William A. Nahhas, Stephanie Green, Jacob B. Green, David S. Alberts, Robert V. O'Toole
Publikováno v:
Investigational new drugs. 9(2)
The Southwest Oncology Group conducted a phase II study of esorubicin treatment in patients with advanced endometrial cancer who had received no prior chemotherapy. Twenty of 31 patients were fully evaluable for response and toxicity. There were no c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f898370b2a1fc87117116dcd26ee0a7
https://pubmed.ncbi.nlm.nih.gov/1874602
https://pubmed.ncbi.nlm.nih.gov/1874602
Publikováno v:
Investigational new drugs. 9(2)
Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were giv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40b32285a2f427d51497a20b7598419
https://pubmed.ncbi.nlm.nih.gov/1651908
https://pubmed.ncbi.nlm.nih.gov/1651908
Publikováno v:
Anti-cancer drugs. 2(1)
A new approach to antitumor analog selection was evaluated using in vitro cytotoxicity assays in tumor cells and heart cells. Eight anthracycline antibiotics and five non-anthracycline DNA intercalating agents were separately exposed to human 8226 my
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0607a0fd718e8c5ab4e8f683d0dd8d
https://pubmed.ncbi.nlm.nih.gov/1958848
https://pubmed.ncbi.nlm.nih.gov/1958848
Publikováno v:
Investigational new drugs. 8(3)
In this phase II trial, twenty patients with advanced, measurable melanoma from ECOG institutions were treated with esorubicin 30 mg/m2 iv every three weeks. Doses were escalated or reduced based on nadir counts. The dose limiting toxicity was leukop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377a9c2650d82fa56bbb53c9328962b3
https://pubmed.ncbi.nlm.nih.gov/2272773
https://pubmed.ncbi.nlm.nih.gov/2272773
Publikováno v:
Investigational new drugs. 8(1)
Esorubicin (4' deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4' position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e87e53f3eff74b0aaebbab463d5381
https://pubmed.ncbi.nlm.nih.gov/2188929
https://pubmed.ncbi.nlm.nih.gov/2188929